MitraClip China PMS

NCT ID: NCT04259411

Last Updated: 2025-12-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-06
• Study Completion Date: 2025-03-07

Brief Summary

The MitraClip System is the first commercially available catheter-based option for the treatment of MR. The MitraClip System was developed as an alternate percutaneous technology which may serve as a viable therapeutic option for open-heart surgery. Treatment with the MitraClip device allows patients to undergo a less invasive procedure that can mechanistically reduce MR and allow for improved quality of life. The MitraClip procedure is performed under general anesthesia without the use of a heart-lung machine, with recovery typically lasting two to three days.

Detailed Description

Mitral regurgitation (MR) is the most common heart valve condition in the world. MR occurs when the mitral valve does not close properly, allowing blood to leak back into the upper chamber of the heart. As a result, the heart may try to pump harder in order to compensate for the decrease in blood flow to the rest of the body. Patients with severe MR suffer from debilitating symptoms such as shortness of breath, heart palpitations, lightheadedness, and fatigue. These patients are at risk of poor quality of life, marked limitation in activity, repeated heart failure hospitalizations, and increased mortality. Chronic severe MR is often associated with heart failure and can lead to death if left untreated.

While mitral valve repair or replacement surgery is currently regarded as standard of care, many patients with clinically significant MR are at an unacceptable risk of morbidity and mortality and are therefore not appropriate surgical candidates. To optimize afterload reduction and treatment of fluid load, these patients are often treated with medical management (i.e., beta blockers, ACE inhibitors, angiotensin II receptor blockers) which may relieve MR symptoms, but does not address the underlying cause of the condition. As a result, a significant portion of patients treated medically continue to progress to heart failure and experience an increasingly debilitating quality of life. A significant unmet clinical need thus exists for the treatment of moderate-to-severe and severe MR in high surgical risk patients.

The MitraClip System has been in clinical use for treatment of significant MR since 2003. The MitraClip System received CE (Conformité Européenne) Mark for both DMR and FMR indications in March 2008 and was approved by FDA for DMR indication in October 2013 and for FMR indication in March 2019. The system is approved for use in more than 102 countries or regions worldwide. More than 100,000 patients have undergone the MitraClip procedure worldwide. On June 15, 2020, the MitraClip System has been approved for clinical use in China.

Conditions

Mitral Regurgitation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MitraClip

Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.

Group Type: EXPERIMENTAL

MitraClip procedure

Intervention Type: DEVICE

MitraClip procedure with MitraClip NTR System or MitraClip XTR System

Interventions

MitraClip procedure

MitraClip procedure with MitraClip NTR System or MitraClip XTR System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subjects is eligible to receive the MitraClip per the current approved MitraClip System IFU. (If any update or amendment on the IFU, the latest version of IFU shall be followed.)

2. Subject is 18 years-old or above.

3. Subjects who give consent for study procedure.

Exclusion Criteria

1. Subject cannot tolerate procedural anticoagulation or anti-platelet regimen.

2. Subject with active endocarditis of mitral valve.

3. Subject with rheumatic mitral valve disease.

4. Subject with echocardiographic evidence of intracardiac, IVC or femoral venous thrombus.

5. Subject is unlikely to survive the protocol follow up period of 12-months after device implant.

6. Subject has insufficient or lost ability to maintain their will and rights.

7. Subject is illiterate.

8. Pregnant or nursing subjects and those who plan pregnancy during the study follow-up period

9. Subject participates in another clinical study that may impact the follow-up or results of this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott Medical Devices

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kyle J Brunner

Role: STUDY_DIRECTOR

Abbott Structural Heart

Locations

Fuwai Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Xiamen Cardiovascular Hospital Xiamen University

Xiamen, Fujian, China

Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen

Shenzhen, Guangdong, China

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

The 2nd Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

Countries

China

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

ABT-CIP-10263

Identifier Type: -

Identifier Source: org_study_id